ExpreS2ion announces financial results for the fourth quarter and full-year 2023 08 February 2024
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces... Read more
Hørsholm, Denmark, 8 February 2024 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) today announces... Read more
CELEBRATION, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more
CELEBRATION, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra... Read more
The Board of Directors of Initiator Pharma A/S, company reg. (CVR) no. 37663808, (“Initiator” or... Read more
Hørsholm, Denmark, 22 January 2024 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies... Read more
Copenhagen, January 22, 2024 – Curasight A/S (“Curasight” or “the Company” – TICKER:... Read more
Pila Pharma and its CEO, Dorte X. Gram, has been selected to participate cost-free in a scale-up program... Read more
Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet... Read more
Today we are pleased to share construction plans for a new manufacturing facility at AGC Inc.’s Yokohama... Read more